Does the Texas LLC structure matter for life sciences insurance underwriting?

Insurance carriers underwrite a named insured — the legal entity on the policy declarations. When you operate as a single Texas LLC, that's straightforward. When you operate as a Texas series LLC with multiple protected series, or as a holding company with multiple subsidiary operating LLCs, the named-insured wording and additional-insured passthrough structure determines whether your sponsor MSA insurance requirements are satisfied or whether you have a coverage gap the carrier and the sponsor would both call a problem.

Texas series LLCs (Texas Business Organizations Code Chapter 101, Subchapter M) allow a single LLC to establish multiple protected series, each with separate assets and liability shields. Insurance treatment is jurisdictionally uneven — some carriers treat each series as a separate insured requiring separate underwriting; others underwrite the parent LLC and treat all series as additional insureds.

For life sciences operators using a series LLC structure to separate compounding operations from a 503B outsourcing facility, or to separate medical device development from commercial sales, the carrier's treatment of the series structure is a material program-design question. Get clarity in writing during the submission process; sponsor MSAs and hospital purchase contracts that name a specific series will reject a COI naming only the parent LLC.

When a biotech operates through a holding company with multiple operating subsidiaries (typical for clinical-stage biotechs with separate research, development, and commercial entities), the insurance program design has two structural choices: per-entity policies or a blanket policy naming all entities as named insureds.

Per-entity policies provide cleaner cost allocation and underwriting alignment with each entity's activities but multiply premium minimums across the structure. Blanket policies offer premium efficiency but require careful named-insured wording to ensure each subsidiary is fully insured for its specific activities.

For D&O specifically, the standard structure is a single blanket D&O policy covering the holding company and all subsidiaries, with the directors and officers of each entity named as insured persons. Carriers underwrite the structure as a whole; rating reflects the consolidated risk profile.

Sponsor MSAs and GPO supplier agreements typically require the sponsor or GPO to be added as additional insured "on a primary, non-contributory basis with respect to liability arising from the named insured's products or services performed for the additional insured." The exact wording matters — generic "additional insured" wording does not always satisfy sponsor counsel, particularly for sophisticated pharma sponsors with detailed MSA insurance exhibits.

CG 20 10 (Additional Insured — Owners, Lessees or Contractors — Ongoing Operations) and CG 20 37 (Additional Insured — Owners, Lessees or Contractors — Completed Operations) are the standard ISO endorsement forms; both are typically required by pharma sponsor MSAs that contemplate both manufacturing services and post-shipment claims.

Mid-policy entity changes (a subsidiary is sold, a new operating entity is formed, the parent reorganizes) require endorsement updates to the named-insured wording. Carriers typically charge no additional premium for adding a new wholly-owned subsidiary mid-term but require notice and an endorsement. Failure to update named-insured wording after a structure change is a common claims-handling problem — the carrier may deny coverage if a claim is brought against an entity not named on the policy.